PDL-1 22C3 Dako

Programmed Death-Ligand 1 (PD-L1) is a protein found on the surface of normal and cancer cells. It plays a key role in helping cancer cells evade the immune system by binding to the PD-1 receptor on immune cells and suppressing their attack.

The PDL-1 22C3 Dako test uses immunohistochemistry (IHC) to detect and measure PD-L1 expression in tumor tissue. The Dako 22C3 pharmDx assay is an FDA-approved companion diagnostic for selecting patients who are likely to benefit from pembrolizumab (Keytruda) and other PD-1/PD-L1 inhibitors.

By analyzing PD-L1 expression, doctors can predict how well a patient’s tumor may respond to immunotherapy. This information helps in personalizing cancer treatment plans and improving clinical outcomes.

Doctors usually recommend this test for patients diagnosed with cancers such as non-small cell lung cancer (NSCLC), melanoma, head and neck cancers, urothelial carcinoma, and gastric cancers.

For this test, it is important to submit the clinical history, histopathology report, previous test results, and a doctor’s prescription at the time of sample collection. The Tata 1mg consolidated Test Requisition Form (TRF) must also be duly filled and submitted.

Lab test results may vary across different laboratories. Abnormal test results require an expert interpretation. Therefore, never try to self-medicate at home based solely on these results, and always consult a doctor for a proper understanding of the test results.

Disclaimer: In no event shall the liability of TATA 1MG exceed the amount of the actual cost of test charges incurred by the customer as stated on the invoice issued by Tata 1mg.